NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=122789&from=3 CLASS P ...

Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing patient reach with KYV-102 using whole blood rapid manufacturing Cash run ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=121991&from=4CLASS PERIOD: T ...

诉讼背景 - 针对Kyverna Therapeutics Inc (NASDAQ: KYTX)的证券集体诉讼已提交 代表在2024年2月8日首次公开募股(IPO)期间或之后购买Kyverna普通股的投资者 [1] - 诉讼指控被告在IPO招股说明书和注册声明中作出重大虚假和/或误导性陈述 未披露公司业务、运营和前景的重要信息 [2] - 具体指控包括被告在IPO时未披露与一项临床试验相关的不利数据 [2] 诉讼程序 - 投资者可在2025年2月7日前申请成为首席原告代表 首席原告通常是具有最大财务利益且能代表拟议投资者群体的投资者 [3] - 首席原告将选择律师代表原告和集体 法院批准的律师将成为首席或集体律师 [3] - 是否担任首席原告不影响投资者分享任何赔偿的权利 [3] 律所信息 - Kessler Topaz Meltzer & Check LLP正在处理此案 该律所在全球范围内提起集体诉讼 已为欺诈和其他公司不当行为的受害者追回数十亿美元 [4] - 律所鼓励遭受重大损失的Kyverna投资者直接联系以获取更多信息 [4] - 律所致力于保护投资者、消费者、员工等免受企业和管理者的欺诈、滥用、不当行为和疏忽 [4]

SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.For more inf ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...

BENSALEM, Pa., Jan. 6, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KYVERNA THERAPEUTICS, INC. (KYTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE FEBRUARY 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact t ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=120456&from=4CLASS PERIOD: Th ...

RADNOR, Pa., Jan. 4, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Kyverna losses, you ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...